Sentences with phrase «developing tuberculosis»

Following news today of two people developing tuberculosis (TB) after contact with a cat infected with «Mycobacterium bovis» (M. bovis), UK charity Cats Protection is keen to reassure people that the risk of contracting the disease from their pet is minimal.

That year he had developed tuberculosis in his arm, and it had spread throughout his body.

New data released by the European Centre for Disease Prevention and Control (ECDC) and WHO / Europe ahead of World TB Day show that an estimated 340,000 Europeans developed tuberculosis (TB) in 2014, corresponding to a rate of 37 cases per 100,000 population.

Not exact matches

If hunger (responsible for more deaths every year than war or disease and the loss of more lives than AIDS, malaria and tuberculosis combined) is not attributable solely to inadequate production of food, but rather insufficient availability of food, why isn't more being done to reduce the shameful levels of food loss occurring in developing countries?

Moreover, your child will be particularly prone to developing respiratory diseases, ear infections, tuberculosis, cancer, food allergies, asthma, short stature and attention disorders.

Colorado State University researchers have developed a device for use in the field that can identify both active tuberculosis infection and dormant microbes, which could flare up into full - blown illness *

«This app has the potential to help in the fight against HIV, tuberculosis and malaria in the developing world, bringing the concept of mobile healthcare to reality,» said Ali Yetisen, a PhD student in the Department of Chemical Engineering & Biotechnology, who led the research.

Public health: Not just a disease of the rich (p 66) To tackle the growing threat from cancer in developing countries, the disease needs to be given the same prominence that has been accorded to HIV, tuberculosis (TB) and malaria in recent years, says Paul Farmer in an interview published in this month's Scientific American.

It is being used to develop vaccines not just for HIV (PDF) but also for malaria and tuberculosis.

Today he directs the Innovations in International Health program at MIT, and his inventions (including an inhalable measles vaccine and a system that monitors tuberculosis treatment) are helping to improve medical access in the developing world.

However, because Mycobacterium tuberculosis has developed many ways to evade the normal immune response, infections become chronic because a stalemate develops between the pathogen and the host.

The concept, published in Trends in Immunology, proposes that current ideas about how tuberculosis develops in patients may be incomplete and that, in fact, infection causes autoimmunity, where the immune system reacts incorrectly to its own tissue.

As a team of researchers from four European countries and South Korea report in Science today, a gene the group dubbed ethA2 is normally inactive in M. tuberculosis, so the bacteria hasn't had a chance to develop resistance to it.

When you launched GHIT the focus was on poverty - exacerbating diseases prevalent in developing nations — HIV, malaria, tuberculosis and neglected tropical diseases such as leprosy and Chagas disease.

However, in a few developing countries, model TB - control programmes supported by the International Union against Tuberculosis and Lung Disease may be limiting the spread of TB.

Scientists at the Central Veterinary Laboratory in Weybridge are conducting field trials on a kit developed for diagnosing tuberculosis in live badgers.

Unfortunately, the majority of MDR tuberculosis cases occur in developing countries that can't afford the several billion dollars that the global Stop TB Partnership estimates3 will be required to combat the disease.

We must strengthen infection control measures, focus on households, health centres, and communities to prevent tuberculosis spreading from person to person, and develop more effective diagnostic tests to rapidly and accurately detect drug resistance.»

It uses data from WHO and surveys estimating the number of drug - resistant tuberculosis cases to predict how many cases of multidrug - resistant and extensively drug - resistant tuberculosis would develop during 2000 and 2040.

n many developing countries, a significant fraction of the tuberculosis burden comes potentially from the tuberculosis bacteria carried by animals, essentially cattle.

Its complex three - dimensional structure allows it to act simultaneously on two parts of a key enzyme in the tuberculosis bacillus, and in doing so, dramatically reduce the risk that the bacteria will develop multiple resistances.

The foundation has grants from companies, government agencies, and other foundations to develop eight new prizes, including competitions involving health care, tuberculosis, and alternative aviation fuels.

The TB bacterium Mycobacterium tuberculosis (Mtb) is estimated to be present in up to a third of the world's population, although active TB only develops in around one in 10 cases.

In strains of tuberculosis that have developed drug resistance mutations, researchers have identified a secondary pathway that can be activated to reinstate drug sensitivity.

More than 10.6 million people worldwide fell ill and 1.7 million died from tuberculosis last year while a quarter of the world has latent TB, which will develop into active tuberculosis for one in ten victims years or even decades later.

Johns Hopkins researchers have developed a computer simulation that helps predict under which circumstances a new short - course treatment regimen for drug - resistant tuberculosis could substantially reduce the global incidence and spread of the disease.

The computer model was developed to help understand the impact of a recommendation issued in May by the World Health Organization for wider use of a new nine - to 12 - month treatment regimen for multidrug - resistant tuberculosis (MDR - TB).

About one - third of the global population is infected with the bacteria that cause TB — Mycobacterium tuberculosis, or Mtb — though only a small percentage will develop the actual disease.

Ethionamide in particular is activated by the enzyme EthA, but some resistant forms of tuberculosis have developed mutations in the ethA gene, sparing them from the toxic effects of the transformed ethionamide.

More than one - third of the world's population is susceptible to active tuberculosis, so it is unfortunate that Sutherlandia, which traditionally is taken to prevent or treat infections, can actually cause them to develop the disease, and perhaps also cause the microbe to become a drug - resistant «super bug.»»

The researchers observed that several patients taking the Southerlandia supplement developed active tuberculosis despite taking Isoniazid.

According to Global Tuberculosis Control 2009, released on World TB Day (24 March), 9.27 million people developed active cases of TB that year, and 1.37 million of these people also had HIV infections.

Children who attend daycare in their first few months are much less likely to develop leukaemia than those who stay at home, for instance, while some tuberculosis vaccines reduce the risk of skin cancer.

Even so, the complex vaccine will be expensive by developing world standards, and its cost - effectiveness is a major issue for vaccine developers and public health experts, says Scott Filler of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Belisle saw that the approaches his team has taken with tuberculosis and leprosy — developing biomarkers or biosignatures for diagnosing a disease or the prognosis for a disease — could be applied to developing a diagnostic test for STARI and improving Lyme disease diagnostic tests.

We carry out translational research programmes to develop infectious disease vaccines, therapeutics and diagnostics using animal models of tuberculosis, influenza, HIV / AIDS, Clostridium difficile, meningococcal disease, chlamydia, burkholderia and anthrax, as well as emerging viral diseases such as Crimean Congo haemorrhagic fever.

Infectious diseases such as HIV / AIDS and tuberculosis continue to rank high among global mortality factors, especially in developing countries, and systemic inflammation has been identified as a root case of many chronic disorders in the developed world.

New vaccines against malaria, tuberculosis and HIV are currently in field trials in the developing world.

is a network to promote clinically oriented research in the field of tuberculosis in Europe by sharing and developing ideas and research protocols

For example, a particular gene variant in the promoter region of the IL10 gene is associated with a 40 to 60 % increased risk of developing active tuberculosis among Europeans and Americans [75].

«Although our goal is to develop systems that can treat infectious diseases such as malaria, HIV or tuberculosis in sub-Saharan Africa or Southeast Asia, there are many applications here in the U.S. for treating chronic conditions such as heart disease, diabetes or psychiatric illness.

The overuse of antibiotics has resulted in several types of bacteria — including the bacteria that causes tuberculosis — to develop resistance to one or more varieties of antibiotics.

Tuberculosis, leishmaniasis and leprosy are the core diseases on which we focus, but our expertise in adjuvant development and formulation extend our reach through partnerships to work on a range of diseases, including malaria, pandemic influenza, Chagas disease, hookworm, shistosomiasis, HIV / AIDS and diseases that are emerging in the developed world, such as chikungunya, Zika and West Nile virus.

It is not only the earliest occurrence of fully - developed hypertrophic pulmonary osteopathy on an adult skeleton to date, but also clearly establishes the presence of tuberculosis in Europe 7,000 years ago.»

Most recently she was a Scientist at Open Source Drug Discovery, a unit of the Indian Government, dedicated to developing and strengthening the contributions of Indian institutes to the entire tuberculosis drug discovery pipeline.

The idea behind a â $ œHuman Vaccine Projectâ $ is to combine efforts at developing vaccines for major (but very different) diseases such as influenza, dengue, HIV, hepatitis C, tuberculosis and malaria, with the rationale that what scientists working on those diseases have in common is the Ray Ban outlet challenge of working with the human immune system.

He has also participated in technology transfer projects in Brazil and India, where a vaccine formulation center has been constructed to manufacture IDRI - developed adjuvant formulations for clinical trials to evaluate malaria, leishmania, and tuberculosis vaccines.

Research Focus: I dedicate my time and effort to develop high - throughput sequencing technologies such as single cell transcriptomic, ChIP - Seq, ChIA - PET, and many more... The scientific rational is to understand better and with a different angle, the mechanisms of epigenetic regulation of gene expression in (rare) immune cells, pathologically relevant in many diseases such as asthma, SLE, tuberculosis...

Developing novel and much needed vaccines for infectious diseases including tuberculosis and leishmaniasis.

He currently serves as principal investigator on a $ 11.9 M contract from the National Institutes of Health (NIH) to develop a thermostable tuberculosis vaccine suitable for distribution in developing countries, involving formulation development, cGMP manufacturing, and clinical testing.